Maternal group B streptococcal immunization: Capsular polysaccharide (CPS)-based vaccines and their implications on prevention

Programa de Pós-Graduação em Ciências da Saúde, Pontifícia Universidade Católica do Paraná, Rua Imaculada Conceição, 1155, Centro de Ciências Biológicas e da Saúde, 2° andar, 80215-901, Prado Velho, Curitiba, Paraná, Brazil.
Vaccine (Impact Factor: 3.62). 03/2011; 29(21):3729-30. DOI: 10.1016/j.vaccine.2011.02.102
Source: PubMed


Group B streptococcal (GBS) capsular polysaccharide (CPS)-based conjugate vaccine, which includes types Ia, Ib, II, III, and V, could potentially prevent neonatal, pediatric, adult, and pregnancy-associated diseases. However, since GBS CPS types included in that vaccine are prevalent serotypes found in North America and Europe, it may not provide the necessary protection for individuals in countries in which other capsular types have been found.

Download full-text


Available from: Sergio Fracalanzza, Aug 12, 2014
22 Reads
  • Source
    • "It is noteworthy that memory B cells are not produced in response to most polysaccharide vaccines, therefore lacking the ability of inducing a booster response. Furthermore, plain polysaccharide vaccines are not generally immunogenic in infants, and their use is not allowed as vaccines to prevent disease in children caused by polysaccharide-encapsulated bacteria that have their highest incidence in the first year of life (Johri et al., 2006; Palmeiro et al., 2011). Therefore, a more recent approach to developing GBS vaccines is to use proteins (Fluegge et al., 2004; Santillan et al., 2008; Papasergi et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the studies was to identify immunogenic proteins of Streptococcus agalactiae (group B streptococcus; GBS) isolates. Investigation of the immunoreactivity with human sera allowed us to determine major immunogenic proteins which might be potential candidates for the development of vaccine. For the study, we have selected 60 genetically different, well-characterized GBS clinical isolates. The proteins immunoreactivity with 24 human sera from patients with GBS infections, carriers, and control group without GBS was detected by SDS-PAGE and Western blotting. As a result, some major immunogenic proteins were identified, of which four proteins with molecular masses of about 45 to 50 kDa, which exhibited the highest immunoreactivity features, were analyzed by LC-MS/MS. The proteins were identified by comparative analysis of peptides masses using MASCOT and statistical analysis. The results showed known molecules such as enolase (47.4 kDa), aldehyde dehydrogenase (50.6 kDa), and ones not previously described such as trigger factor (47 kDa) and elongation factor Tu (44 kDa). The preliminary results indicated that some GBS proteins that elicit protective immunity hold promise not only as components in a vaccine as antigens but also as carriers or adjuvants in polysaccharide conjugate vaccines, but more studies are needed.
    FEMS Microbiology Letters 10/2013; 349(1). DOI:10.1111/1574-6968.12292 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: During a national surveillance program on Group B streptococci (GBS) maternal carriage and neonatal infections, a GBS strain isolated from a pregnant woman's vagino-rectal swab was non typable by either serological or molecular methods. Further molecular characterization demonstrated that the strain lacked the entire capsular locus, possibly by a recombination event that excised a 14,1 Kbase pairs genomic fragment extending from the regulatory protein cpsX gene to the neuA gene. The natural loss of the capsular locus by GBS isolated from a human has never been described so far. Such an event, while possibly a dead-end from the evolutionary point of view, leaves a still able-to-colonize organism unrecognizable by the vaccines currently under development.
    European Journal of Clinical Microbiology 05/2011; 31(3):233-5. DOI:10.1007/s10096-011-1298-7 · 2.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the widespread implementation of several effective vaccines over the past few decades, bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis and Group B Streptococcus (GBS) still results in unacceptably high levels of human mortality and morbidity. A residual disease burden due to bacterial meningitis is also apparent due to a number of persistent or emerging pathogens, including Mycobacterium tuberculosis, Escherichia coli, Staphylococcus aureus, Salmonella spp. and Streptococcus suis. Here, we review the current status of bacterial meningitis caused by these pathogens, highlighting how past and present vaccination programs have attempted to counter these pathogens. We discuss how improved pathogen surveillance, implementation of current vaccines, and development of novel vaccines may be expected to further reduce bacterial meningitis and related diseases in the future.
    Vaccine 04/2012; 30 Suppl 2:B78-86. DOI:10.1016/j.vaccine.2011.12.099 · 3.62 Impact Factor
Show more